Erasca and Bristol Myers Squibb launch Phase 1/2 trial of ERAS-0015 with navlimetostat in MTAP‑deleted pancreatic cancer
+1 new source since this summary was written
Erasca (ERAS) and Bristol Myers Squibb (BMY) have entered a non‑exclusive collaboration to study a combination of Erasca’s pan‑RAS molecular glue ERAS‑0015 and BMY’s PRMT5 inhibitor navlimetostat in patients with MTAP‑deleted pancreatic ductal adenocarcinoma. Bristol Myers Squibb will sponsor the Phase 1/2 trial while Erasca will supply ERAS‑0015. Both companies retain development and commercialization rights to their respective compounds.
Why it matters
The partnership gives Erasca access to a major pharma sponsor and may accelerate clinical data generation for ERAS‑0015, potentially enhancing the company’s valuation. Investors should watch trial enrollment and results, which could affect ERAS share price.
Key facts
- 1Erasca and Bristol Myers Squibb announced a collaboration to evaluate ERAS‑0015 with navlimetostat in a Phase 1/2 trial for MTAP‑deleted pancreatic ductal adenocarcinoma. rttnews.com
- 2Bristol Myers Squibb will sponsor the study; Erasca will supply ERAS‑0015. rttnews.com
- 3The agreement is non‑exclusive and each company retains development and commercialization rights to its drug. rttnews.com
- 4ERAS stock closed at $13.89, down 8.07% on the day of the announcement. rttnews.com
- 5During after‑hours trading the stock was at $14.31, up 3.05%. rttnews.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.